Arvinas News

Arvinas to Present at Upcoming Investor Conferences

NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann

ArvinasMay 2 00:00 ET

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In ...

PR NewswireApr 30 10:30 ET

Express News | Arvinas Appoints Randy Teel, Ph.d., as Chief Business Officer

Moomoo 24/7Apr 24 16:30 ET

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today a

ArvinasApr 24 00:00 ET

Analyst Forecasts For Arvinas, Inc. (NASDAQ:ARVN) Are Surging Higher

Arvinas, Inc. (NASDAQ:ARVN) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased their rev

Simply Wall StApr 17 15:58 ET

Express News | HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $87

Moomoo 24/7Apr 15 07:28 ET

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Yahoo FinanceApr 12 13:55 ET

Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)

TipRanksApr 12 08:29 ET

Arvinas Is Maintained at Buy by HC Wainwright & Co.

Arvinas Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 12 07:25 ET

Arvinas Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 133.49% HC Wainwright & Co. $90 → $87 Maintains Buy 03/25/2024 74.45% Truist Securities → $65 R

BenzingaApr 12 07:14 ET

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)

TipRanksApr 12 07:10 ET

Express News | Arvinas, Inc. : H.c. Wainwright Cuts Target Price to $87 From $90

Moomoo 24/7Apr 12 06:53 ET

Novartis (NVS.US) received Arvinas's potential “best-in-class” proteolytic agent for over $1 billion

Arvinas (ARVN.US) announced that it has reached an exclusive strategic licensing agreement with Novartis/NVS.us (Novartis/NVS.us).

Zhitong FinanceApr 11 21:37 ET

Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential

TipRanksApr 11 13:05 ET

Fastenal, CarMax Fall; Alpine Immune Sciences, Arvinas Rise, Thursday, 4/11/2024

BarchartApr 11 12:25 ET

Express News | Arvinas Inc : Wedbush Cuts Target Price to $57 From $59

Moomoo 24/7Apr 11 10:49 ET

Express News | Arvinas Shares up 6.1% Co Enters Into Global License Agreement With Novartis for Prostate Cancer Drug

Moomoo 24/7Apr 11 09:33 ET

UPDATE 2-Novartis Taps Arvinas' Cancer Drug for up to $1 Billion

Yahoo FinanceApr 11 08:59 ET

Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis

Arvinas (ARVN) said Thursday it has entered into agreements with Novartis (NVS) for the development and commercialization of its ARV-766 prostate cancer treatment and the sale of its AR-V7 preclinical program.

MT NewswiresApr 11 08:56 ET

Express News | Arvinas Shares Are Trading Higher After the Company Entered a License Agreement With Novartis for the Development and Commercialization of ARV-766 in Prostate Cancer Treatment

Moomoo 24/7Apr 11 07:25 ET